研究单位：[1]Gilead Sciences[2]Tongji Hospital, Tongji Medical college HuaZhong University of Science&Technology Wuhan, Hubei, China, 430030[3]Nanjing No. 2 Hospital Nanjing, Jiangsu, China[4]The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China, 330006[5]The First Hospital of Jilin University Changchun, Jilin, China, 130021[6]The sixth People's Hospital of Shenyang Shenyang, Liaoning, China, 110006[7]Jinan Infectious Disease Hospital Jinan, Shandong, China, 250021[8]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041[9]No.1 Hospital Affiliated to Kunming Medical College Kunming, Yunnan, China, 650032[10]Beijing Ditan Hospital Beijing, China, 100015[11]No. 302 PLA Hospital Beijing, China, 100039[12]Peking University People's Hospital Beijing, China, 100044[13]Beijing Friendship Hospital, Capital Medical University Beijing, China, 100050[14]Beijing Youan Hospital, Capital Medical University Beijing, China, 100069[15]The 2nd Xiangya Hospital Central South University Changsha, China, 410011[16]Guangzhou No.8 People's Hospital Guangzhou, China, 510060[17]Nanfang Medical University, Nanfang Hospital Guangzhou, China, 510515[18]The People's Hospital of Hainan Province Haikou, China, 570311[19]Jiangsu Provincial People's Hospital Nanjing, China, 210029[20]Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Shanghai, China, 200025[21]Shanghai Public Health Clinical Center Shanghai, China, 200083[22]85 Hospital of People's Liberation Army Shanghai, China, 200235
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection in China.
